Erratum: An update on the evaluation and management of pulmonary hypertension in scleroderma (Current Rheumatology Reports (2012) 14 (1-10) DOI: 10.1007/s11926-011-0226-2);An update on the evaluation and management of pulmonary hypertension in scleroderma

Current Rheumatology Reports

Volumn 14, Issue 1, 2012, Pages 1-10

  Coghlan, John G ^a   Schrieber, Benjamin ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Breathlessness; Combination therapy; Endothelin receptor antagonist; Goal oriented therapy; PAH; PH; Phosphodiesterase inhibitor; Prostanoid; Pulmonary arterial hypertension; Pulmonary hypertension; Pulmonary veno occlusive disease; PVOD; Scleroderma; Screening; Systemic sclerosis

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CICLETANINE; DIGOXIN; DIURETIC AGENT; ILOPROST; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MACITENTAN; OXYGEN; PLACEBO; PROSTACYCLIN; RIOCIGUAT; SELEXIPAG; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

ADULT RESPIRATORY DISTRESS SYNDROME; ANALYTICAL PARAMETERS; ANTICOAGULATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL EVALUATION; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DIFFUSE ALVEOLAR DAMAGE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DYSPNEA; EXERCISE; HEART DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LABORATORY TEST; LUNG DISEASE; LUNG VASCULAR RESISTANCE; MONOTHERAPY; OXYGEN THERAPY; PREDICTIVE VALUE; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SENSITIVITY AND SPECIFICITY; STOMACH ANTRUM VASCULAR ECTASIA; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASODILATATION;

EID: 84855172215     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0250-x     Document Type: Erratum

References (63)

1. Rich S, ed. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6-10, 1998, cosponsored by the World Health Organization.
2. G Simonneau IM Robbins M Beghetti, et al. 2009 Updated clinical classification of pulmonary hypertension J Am Coll Cardiol. 54 1 Suppl S43 54 19555858 10.1016/j.jacc.2009.04.012
3. R Condliffe DG Kiely AJ Peacock, et al. 2009 Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era Am J Respir Crit Care Med 179 2 151 7 18931333 10.1164/rccm.200806-953OC This is an overview of all connective tissue disease-associated PH in a single country, providing insights into prevalence, incidence, and survival
4. CD Cool D Kennedy NF Voelkel, et al. 1997 Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection Hum Pathol 28 434 442 9104943 1:STN:280:DyaK2s3lvVOksA%3D%3D 10.1016/S0046-8177(97)90032-0 (Pubitemid 27175084)
5. N Voelkel R Tuder 1995 Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension Eur Respir J 8 2129 38 8666110 1:STN:280:DyaK283mtl2jsw%3D%3D 10.1183/09031936.95.08122129
6. P Dorfmüller M Humbert F Perros, et al. 2007 Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases Hum Pathol 38 893 902 17376507 10.1016/j.humpath. 2006.11.022 (Pubitemid 46735956)
7. DS O'Callaghan P Dorfmuller X Jaïs, et al. 2011 Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? Presse Med. 40 1 Pt 2 e65 78 21211937
8. J Avouac P Airo C Meune, et al. 2010 Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and Meta-analysis of 5 studies J Rheumatol 37 2290 8 20810505 10.3899/jrheum.100245 This is an overview of the prevalence of SSc-associated PAH using current diagnostic pathways; the very low prevalence of PVOD is noteworthy
9. MJ Overbeek MC Vonk A Boonstra, et al. 2009 Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy Eur Respir J 34 371 379 19282344 1:STN:280:DC%2BD1MrisFGmtg%3D%3D 10.1183/09031936.00106008 Pathological insights into the poor prognostic outcome in SSc-associated PAH note that the high prevalence of histopathological PVOD contrasts with a relatively low incidence of clinical PVOD
10. DB Badesch VF Tapson MD McGoon, et al. 2000 Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 6 425 34 10733441 1:CAS:528:DC%2BD3cXit1SmsL8%3D (Pubitemid 30149039)
11. E Hachulla V Gressin L Guillevin, et al. 2005 Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study Arthritis Rheum. 52 12 3792 800 16320330 10.1002/art.21433 (Pubitemid 41798217)
12. D Mukerjee D St. George B Coleiro, et al. 2003 Prevalence & outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach Ann Rheum Dis 62 1088 93 14583573 1:STN:280: DC%2BD3srgslKquw%3D%3D 10.1136/ard.62.11.1088 (Pubitemid 37323574)
13. AE Doyle JF Goodwin CV Harrison RE Steiner 1957 Pulmonary vascular patterns in pulmonary hypertension Br Heart J. 19 3 353 65 13446319 1:STN:280:DyaG2s%2FptlSqsA%3D%3D 10.1136/hrt.19.3.353
14. S Rich M Rabinovitch 2008 Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension Circulation 118 2190 2199 19015413 10.1161/CIRCULATIONAHA.107.723007
15. PK Nair RL Kormos JJ Teuteberg, et al. 2010 Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension J Heart Lung Transplant. 29 2 201 8 20113910 10.1016/j.healun.2009.09.013
16. M Fawzy A Osman V Nambiar, et al. 2008 Immediate and long-term results of mitral balloon valvuloplasty in patients with severe pulmonary hypertension J Heart Valve Dis 17 485 491 18980082
17. RM Califf KF Adams WJ McKenna, et al. 1997 A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST) Am Heart J 134 44 54 9266782 1:CAS:528:DyaK2sXls1Wjt78%3D 10.1016/S0002-8703(97)70105-4 (Pubitemid 27329022)
18. PR Kalra JC Moon AJ Coats 2002 Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 85 2-3 195 7 12208583 10.1016/S0167-5273(02)00182-1 (Pubitemid 35245980)
19. I Anand J McMurray JN Cohn, et al. 2004 Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial Lancet 364 9431 347 54 15276394 1:CAS:528: DC%2BD2cXmtVSktbg%3D 10.1016/S0140-6736(04)16723-8 (Pubitemid 38970011)
20. MR Shah SS Stinnett SE McNulty, et al. 2001 Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST Am Heart J 141 908 11376303 1:CAS:528:DC%2BD3MXks1Kmsb8%3D 10.1067/mhj.2001.115299 (Pubitemid 32477001)
21. AL Hachulla D Launay V Gaxotte, et al. 2009 Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients Ann Rheum Dis. 68 12 1878 84 19054830 10.1136/ard.2008.095836
22. SI Nihtyanova EC Tang JG Coghlan, et al. 2010 Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study QJM 103 2 109 15 19966313 1:STN:280:DC%2BC3c%2FktFWitQ%3D%3D 10.1093/qjmed/hcp174 This is a comparison of incidence cases in two eras a decade apart showing that improved screening, while leading to increased recognition of organ-based complications, is associated with improved survival
23. N Goh S Desai S Veeraraghavan, et al. 2008 Interstitial lung disease in systemic sclerosis: a simple staging system Am J Respir Crit Care Med 177 1248 1254 18369202 10.1164/rccm.200706-877OC (Pubitemid 351860934)
24. MM Hoeper S Andreas A Bastian, et al. 2010 Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010 Dtsch Med Wochenschr 135 Suppl 3 S115 24 20862620 10.1055/s-0030-1263318
25. R Condliffe DG Kiely JS Gibbs, et al. 2009 Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension Eur Respir J. 33 2 332 8 18829679 1:STN:280:DC%2BD1M7gs12ltQ%3D%3D 10.1183/09031936.00092008
26. O Sitbon M Humbert V Ioos, et al. 2003 Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? [abstract] Am J Respir Crit Care Med. 167 A440
27. Zhou X-h, Obuchowski NA, McClish DK. Statistical methods in diagnostic medicine. New York: Wiley-Interscience; 2002.
28. Schreiber B, Valerio C, Keir G, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011;63(11):3531-9.
29. JJ Tolle AB Waxman TL Van Horn, et al. 2008 Exercise-induced pulmonary arterial hypertension Circulation 118 21 2183 2189 18981305 10.1161/ CIRCULATIONAHA.108.787101
30. Valerio CJ, Schreiber BE, Handler C, et al. Borderline pulmonary hypertension a prognostically relevant group? Insights from a scleroderma cohort. Eur Heart J (submitted).
31. N Galiè MM Hoeper M Humbert, et al. 2009 Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 20 2493 537 19713419 10.1093/eurheartj/ehp297 This is a pivotal statement of consensus approach to diagnosis and management of PAH in 2009
32. SR Johnson S Mehta JT Granton 2006 Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review Eur Respir J 28 999 1004 17074918 1:STN:280:DC%2BD28njvVGrsQ%3D%3D 10.1183/09031936.06.00015206 (Pubitemid 46331971)
33. Ludwicka-Bradley A, Silver RM, Bogatkevich GS. Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum 2010 (epub ahead of print PMID: 21168185).
34. O Sanchez O Sitbon X Jaïs, et al. 2006 Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension Chest. 130 1 182 9 16840400 1:CAS:528:DC%2BD28Xot1KjtLg%3D 10.1378/chest.130.1.182 (Pubitemid 44116858)
35. T Ito K Ozawa K Shimada 2007 Current drug targets and future therapy of pulmonary arterial hypertension Curr Med Chem 14 6 719 33 17346158 1:CAS:528:DC%2BD2sXisFCmsL8%3D 10.2174/092986707780059562 (Pubitemid 46477723)
36. LJ Rubin DB Badesch RJ Barst, et al. 2002 Bosentan therapy for pulmonary arterial hypertension N Engl J Med. 346 12 896 903 11907289 1:CAS:528: DC%2BD38Xit1ekur0%3D 10.1056/NEJMoa012212 (Pubitemid 34984638)
37. RN Channick G Simonneau O Sitbon, et al. 2001 Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 9288 1119 23 11597664 1:CAS:528:DC%2BD3MXntlOrurs%3D 10.1016/S0140-6736(01)06250-X (Pubitemid 32971843)
38. Galie N, Hoeper MM, Jansa P, et al. Bosentan improves hemodynamics and delays time to clinical worsening in patients with mildly symptomatic Pulmonary Arterial Hypertension (PAH): results of the EARLY study. European Heart Journal 28[suppl.1], 140. 2007. Ref Type: Abstract.
39. Denton CP, Pope JE, Peter HH, et al and (on behalf of the TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators). Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008;67:1222-1228.
40. C Denton J Pope H Peter, et al. 2009 Four-Year Survival in the TRUST cohort of bosentan-treated patients with pulmonary arterial hypertension related to connective tissue disease Arthritis Rheum 60 Suppl 10 438 Abstract
41. MH Williams C Das CE Handler, et al. 2006 Systemic sclerosis associated pulmonary hypertension: improved survival in the current era Heart 92 7 926 32 16339813 1:STN:280:DC%2BD28zmtVKmsw%3D%3D 10.1136/hrt.2005.069484 (Pubitemid 43974055)
42. RJ Barst D Langleben D Badesch, et al. 2006 Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan J Am Coll Cardiol. 47 10 2049 56 16697324 1:CAS:528: DC%2BD28XksFalsbs%3D 10.1016/j.jacc.2006.01.057
43. D Langleben T Brock R Dixon R Barst 2004 STRIDE 1: effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials J Cardiovasc Pharmacol 44 S80 S84 15838366 1:CAS:528:DC%2BD2MXjvVCgsA%3D%3D 10.1097/01.fjc.0000166207.74178. d0 (Pubitemid 40039649)
44. Oudiz R. Functional class improvement with sitaxsentan in patients with class II-IV Pulmonary Arterial Hypertension (PAH). ATS May 2006 A824.
45. Siebold J. Sitaxsentan, a selective endothelin-a receptor antagonist, improves exercise capacity in Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Disease (CTD). Chest 2005: A2704.
46. RL Benza RJ Barst N Galiè, et al. 2008 Sitaxsentan for the treatment of pulmonary arterial hypertension. a 1-year, prospective, open-label observation of outcome and survival Chest 134 775 782 18625676 10.1378/chest.07-0767
47. CJ Valerio CE Handler P Kabunga, et al. 2010 Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension Rheumatology (Oxford). 49 11 2147 53 1:CAS:528: DC%2BC3cXhtlShsLnE 10.1093/rheumatology/keq241
48. N Galiè H Olschewski RJ Oudiz, et al. 2008 Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation. 117 23 3010 9 18506008 10.1161/CIRCULATIONAHA.107.742510
49. Data on file GlaxoSmithKline AMB 029 & 037.
50. N Galie HA Ghofrani A Torbicki, et al. 2005 Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 20 2148 57 16291984 1:CAS:528:DC%2BD2MXht1ajtb%2FI 10.1056/NEJMoa050010 (Pubitemid 41653106)
51. N Galiè BH Brundage HA Ghofrani, et al. 2009 Tadalafil therapy for pulmonary arterial hypertension Circulation 119 22 2894 903 19470885 10.1161/CIRCULATIONAHA.108.839274
52. DB Badesch VF Tapson MD McGoon, et al. 2000 Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 6 425 34 10733441 1:CAS:528:DC%2BD3cXit1SmsL8%3D (Pubitemid 30149039)
53. RJ Barst M McGoon V McLaughlin, et al. 2003 Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 12 2119 25 12821234 1:CAS:528:DC%2BD3sXnvVSqsLs%3D 10.1016/S0735-1097(03)00463-7 (Pubitemid 36724255)
54. G Simonneau RJ Barst N Galiè R Naeije S Rich RC Bourge, et al. 2002 Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomised, placebo-controlled trial Am J Respir Crit Care Med 165 800 4 11897647 (Pubitemid 34229650)
55. G Simmoneau L Rubin N Galie, et al. 2008 Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med. 149 8 521 30
56. Effects of the combination of Bosentan and sildenafil versus sildenafil monotherapy on Pulmonary Arterial Hypertension (PAH) (Compass 2). ClinicalTrials.gov Identifier: NCT00303459.
57. O Sitbon M Humbert H Nunes, et al. 2002 Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 780 788 12204511 1:CAS:528:DC%2BD38XntVKjsr0%3D 10.1016/S0735-1097(02)02012-0 (Pubitemid 34925627)
58. MH Williams CE Handler R Akram, et al. 2006 Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension Eur Heart J 27 1485 1494 16682379 1:CAS:528:DC%2BD28Xnt1Giu7o%3D 10.1093/eurheartj/ehi891 (Pubitemid 43998084)
59. PR Forfia MR Fisher SC Mathai, et al. 2006 Tricuspid annular displacement predicts survival in pulmonary hypertension Am J Respir Crit Care Med 174 1034 1041 16888289 10.1164/rccm.200604-547OC (Pubitemid 44684453)
60. RL Benza DP Miller M Gomberg-Maitland, et al. 2010 Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation. 122 2 164 72 20585012 10.1161/CIRCULATIONAHA.109.898122
61. L Chung J Liu L Parsons, et al. 2010 Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype Chest. 138 6 1383 94 20507945 10.1378/chest.10-0260
62. Condliffe R. Disease progression in systemic sclerosis associated pulmonary hypertension. In: Abraham D, et al editors. Advances in Vascular Medicine. 2010. Part 5, 289-303.
63. D Launay O Sitbon J LePavec, et al. 2010 Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil Rheumatology 49 490 500 20015974 1:CAS:528:DC%2BC3cXitFaqu7s%3D 10.1093/rheumatology/kep398